 Product Service News
June 1, 2024
Rapid Advances in Neurosurgical Technology Drive Revenue Growth for ClearPoint Neuro Inc. ClearPoint Neuro, a leading provider of innovative medical devices for neurological procedures, recently announced the full market release of two groundbreaking technologies - the SmartFrame OR and the Prism Laser Therapy Syste...
|
Clinical Study
June 1, 2024
Y-mAbs Announces Promising Phase 2 Data for Naxitamab in the Treatment of High-Risk NeuroblastomaNEW YORK, June 01, 2024 - Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeuti...
|
Clinical Study
June 1, 2024
:Kymera Therapeutics has presented encouraging new clinical data regarding the ongoing Phase 1 trial of MDM2 Degrader KT-253 at the American Society of Clinical Oncology (ASCO) Annual Meeting. These findings demonstrate initial clinical proof of concept in patients with tumor types that have shown sensitivity to KT-...
|
|
 Clinical Study
June 1, 2024
A Promising Step Forward in Glioblastoma Treatment: BDTX-1535 Shows Encouraging Clinical Data Recurrent glioblastoma multiforme (GBM), a highly aggressive malignant brain tumor, remains one of the most challenging cancers to treat due to its resistance to conventional therapies and poor prognosis. In the ongoing p...
 Product Service News
June 1, 2024
CRB-701 (SYS6002): Promising Results in Targeting Nectin-4 Positive TumorsCorbus Pharmaceuticals Holdings, Inc. has recently announced encouraging safety and efficacy results for their next-generation antibody drug conjugate, SYS6002 (CRB-701), in patients with Nectin-4 positive tumors. The clinical update of this o...
|
|
Our most Popular Articles
|
Personnel Announcements
February 15, 2024
In a recent press release, TTEC Holdings, Inc. (NASDAQ: TTEC), a prominent global CX technology and services innovator, has revealed the appointment of Kenny Wagers as its new Chief Financial Officer. This strategic move aims to strengthen the company s senior executive leadership team. However, recent fin...
|
Stocks on the Move
July 3, 2024
As the summer kicks into high gear, our team of editors at CSIMarket.com has been hard at work testing out a multitude of products. After extensive research and rigorous trials, we have handpicked 12 exceptional items that we wholeheartedly recommend to our friends, family, and readers.1. Laco Sac: The CF Toronto ...
|
Product Service News
August 26, 2024
Rackspace Introduces Innovative Cloud Solutions Amidst Mixed Financial Performance Rackspace Technology Inc. has recently announced the launch of an on-demand Software as a Service (SaaS) offering designed to help organizations emulate complex IT environments. This innovative approach, branded as Rackspace Lab Servi...
|
|
|
Company News
|
Clinical Study
June 1, 2024
Y-mAbs Announces Promising Phase 2 Data for Naxitamab in the Treatment of High-Risk NeuroblastomaNEW YORK, June 01, 2024 - Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeuti...
|
Clinical Study
June 1, 2024
:Kymera Therapeutics has presented encouraging new clinical data regarding the ongoing Phase 1 trial of MDM2 Degrader KT-253 at the American Society of Clinical Oncology (ASCO) Annual Meeting. These findings demonstrate initial clinical proof of concept in patients with tumor types that have shown sensitivity to KT-...
|
Clinical Study
June 1, 2024
Molecular Partners, a pioneering clinical-stage biotech company, recently disclosed the positive outcomes of its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. This article aims to provide an overview of the final data presented by Molecular Partner...
|
|
|
Company News
 Announcement
June 1, 2024
|
Company News
 Clinical Study
June 1, 2024
|
Company News
 Partnership
June 1, 2024
|
More Company News
|
Management Announcement
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
Business Update
June 1, 2024
|
|
|
|
Related News
|
Business Update
|
Business Update
|
|
Stocks
|
Business Update
|
Business Update
|
|
Management Announcement
|
|
|
|
Business News
|
 Clinical Study
A Promising Step Forward in Glioblastoma Treatment: BDTX-1535 Shows Encouraging Clinical Data Recurrent glioblastoma multiforme (GBM), a highly aggressive malignant brain tumor, remains one of the most challenging cancers to treat due to its resistance to conventional therapies and poor prognosis. In the ongoing p...
|
|
Product Service News
CRB-701 (SYS6002): Promising Results in Targeting Nectin-4 Positive TumorsCorbus Pharmaceuticals Holdings, Inc. has recently announced encouraging safety and efficacy results for their next-generation antibody drug conjugate, SYS6002 (CRB-701), in patients with Nectin-4 positive tumors. The clinical update of this o...
|
 Announcement
Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Shows Promising Results in Phase 2 Trial for Previously Treated Metastatic Non-small Cell Lung CancerCOPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 - Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) have recently anno...
|
|
Clinical Study
In the constant battle against cancer, new advancements in treatment options bring hope to patients and healthcare professionals alike. Werewolf Therapeutics, a biopharmaceutical company focused on developing innovative therapies for cancer and immune-mediated diseases, has been at the forefront of groundbreaking re...
|
 Product Service News
Rapid Advances in Neurosurgical Technology Drive Revenue Growth for ClearPoint Neuro Inc. ClearPoint Neuro, a leading provider of innovative medical devices for neurological procedures, recently announced the full market release of two groundbreaking technologies - the SmartFrame OR and the Prism Laser Therapy Syste...
|
Our Most Popular Articles
|
 Personnel Announcements
In a recent press release, TTEC Holdings, Inc. (NASDAQ: TTEC), a prominent global CX technology and services innovator, has revealed the appointment of Kenny Wagers as its new Chief Financial Officer. This strategic move aims to strengthen the company s senior executive leadership team. However, recent fin...
|
 Stocks on the Move
As the summer kicks into high gear, our team of editors at CSIMarket.com has been hard at work testing out a multitude of products. After extensive research and rigorous trials, we have handpicked 12 exceptional items that we wholeheartedly recommend to our friends, family, and readers.1. Laco Sac: The CF Toronto ...
|
 Product Service News
Rackspace Introduces Innovative Cloud Solutions Amidst Mixed Financial Performance Rackspace Technology Inc. has recently announced the launch of an on-demand Software as a Service (SaaS) offering designed to help organizations emulate complex IT environments. This innovative approach, branded as Rackspace Lab Servi...
|
More News
|
 Clinical Study
Y-mAbs Announces Promising Phase 2 Data for Naxitamab in the Treatment of High-Risk NeuroblastomaNEW YORK, June 01, 2024 - Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeuti...
|
 Clinical Study
:Kymera Therapeutics has presented encouraging new clinical data regarding the ongoing Phase 1 trial of MDM2 Degrader KT-253 at the American Society of Clinical Oncology (ASCO) Annual Meeting. These findings demonstrate initial clinical proof of concept in patients with tumor types that have shown sensitivity to KT-...
|
 Clinical Study
Molecular Partners, a pioneering clinical-stage biotech company, recently disclosed the positive outcomes of its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. This article aims to provide an overview of the final data presented by Molecular Partner...
|
 Announcement
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), renowned for pushing the boundaries of cancer treatment, has announced strikingly positive interim results from their ongoing Phase 2 study of CM24, a pioneering therapy for metastatic pancreatic ductal adenocarcinoma (PDAC). Unveiled at the prestigious 2024 American Society ...
|
 Clinical Study
Pioneering Progress: Cullinan Therapeutics Announces Promising Results from the Phase 2b REZILIENT1 Study of Zipalertinib in NSCLC with EGFR Exon 20 Insertion Mutations In the ever-evolving landscape of oncology research, achieving meaningful outcomes for patients with non-small cell lung cancer (NSCLC) remains an ...
|
 Partnership
NIO Inc. Records Historic Monthly Deliveries in May 2024 In an impressive milestone for the Chinese electric vehicle manufacturer, NIO Inc. announced a record-breaking achievement in its May 2024 delivery update. The company’s performance reflected growing market penetration and robust consumer demand in an increa...
|
 Management Announcement
In a stunning display of success, XPENG Motors, a leading Chinese electric vehicle (EV) manufacturer, announced its vehicle delivery results for May 2024. The company reported a remarkable 35% year-over-year increase, with an impressive tally of 10,146 vehicles delivered during the month. This extraordinar...
|
 Business Update
Westlake Chemical Partners Provides 2023 Tax Reporting Information and UpdatesIn a recent announcement, Westlake Chemical Partners, LP (NYSE: WLKP), a chemical and plastics manufacturer, has provided important information regarding tax reporting for the year 2023. The company stated that it will report items of inte...
|
 Business Update
Camden Property Trust Announces Strong Second Quarter Operating Update at Nareits REITweek 2024 Investor ConferenceHouston-based real estate investment trust, Camden Property Trust (CPT), revealed their participation in the highly anticipated Nareits REITweek 2024 Investor Conference during the period of June 3-6, 2...
|
 Business Update
AVALONBAY COMMUNITIES, INC. (NYSE: AVB), a leading real estate investment trust (REIT) focusing on the development, acquisition, and operation of multifamily communities, recently announced its participation in several prominent industry events and published presentations to update investors on its operating perfor...
|
 Business Update
Wipro Expands Retail Sales Channels in Collaboration with Cisco and AT&TIn a strategic move to enhance its retail sales capabilities, global IT consulting and technology services company, Wipro Limited, has announced the expansion of functionalities within Wipro VisionEDGE+. This enhanced offering, developed through...
|
 Business Update
Mirum Pharmaceuticals Receives Positive CHMP Opinion for LIVMARLI (Maralixibat) Oral Solution in Treating Progressive Familial Intrahepatic Cholestasis in Patients as Young as Three Months Foster City, California, USA A Landmark Achievement in Pediatric HepatologyMirum Pharmaceuticals, Inc., listed on NASDAQ unde...
|
 Business Update
Equity Awards Approved as Employment Inducement for New Hires at Sarepta Therapeutics CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), renowned for pioneering precision genetic medicine aimed at addressing rare diseases, has recently announced significant equity awards to new hires. This move, aligned with the company s commitment to attracting top-tier talent, was carried out under Nasdaq Listing Rule 5635(c)(4) and reflects Sarepta s ongoing efforts to reinforce its innovative workforce.On May 31, 2024, Sarepta Therapeutics granted equity awards to nine individuals who joined the company in the same month. These awards were sanctioned by the Compensation Committee of the Board of Directors under the 2024 Employment Commencement Incentive Plan. The inducement grants are not only a symbol of the company’s enthusiasm in bringing aboard new employees but also serve as a substantial motivator for their sustained contribution and commitment towards Sarepta s mission of advancing precise genetic therapies.
|
 Business Update
Four Corners Property Trust (NYSE: FCPT), a distinguished real estate investment trust (REIT) known for its strategic ownership and acquisition of premier, net-leased restaurant and retail properties, is elated to announce a new addition to its burgeoning portfolio. FCPT has successfully completed the acquisition of...
|
 Business Update
In a bid to strengthen its foothold in the rapidly growing European data center market, global power management company Eaton (NYSE: ETN) has recently completed a significant strategic investment in NordicEPOD AS. This move comes as Eaton aims to capitalize on the Nordic region s increasing demand for standardized p...
|
 Business Update
Medical Properties Trust (MPT), a leading real estate investment trust specializing in healthcare facilities, has recently published its third annual Corporate Responsibility Report (CRR). This report sheds light on the company s commitment to environmental sustainability, social responsibility, and corporate gover...
|
|
|
|
|
